Plain-English translation of NCT07407465 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for people with advanced colorectal cancer that has spread or cannot be surgically removed. The study combines three medications: trastuzumab-deruxtecan, , and . Researchers believe this combination may help shrink tumors and improve outcomes for patients whose cancer has a specific genetic feature.
Most colorectal cancers don't have the HER2 genetic marker, so they've been harder to treat with newer targeted medications. This trial exists to see if this medication combination can work better for the small group of patients who do have HER2-positive colorectal cancer.
You likely qualify if…
You likely don't qualify if…
You would receive three medications on a repeating 3-week schedule: an intravenous infusion of trastuzumab-deruxtecan, oral pills taken twice daily for 2 weeks, and an intravenous infusion of . You would continue this treatment as long as it is working and you are tolerating it well. Throughout the trial, you'll have regular blood tests, imaging scans, and clinic visits to monitor how you're responding and check for any side effects.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
France